substances detected in the product under normal storage or use conditions. Both can impact product quality, safety, and efficacy, necessitating thorough evaluation and control in GMP frameworks.

The unique formulation and physical characteristics of different dosage forms influence their vulnerability to E&L. For example, parenteral preparations that bypass the body’s natural barriers require exceptionally low levels of contamination, while solid oral dosage forms have different interaction profiles influenced by tablet manufacturing or capsule GMP processes. Topical and inhalation products introduce further complexity due to direct contact with skin or respiratory mucosa.

Industry guidelines, including EMA’s guidance on extractables and leachables and FDA expectations described in 21 CFR Parts 210 and 211, emphasize risk-based assessment and control strategies. These include materials characterization, toxicological evaluation, and analytical method validation as integral GMP elements.

Recognizing the dosage form-specific interaction mechanisms allows pharmaceutical manufacturers to align GMP controls for extractables and leachables with regulatory expectations and product safety requirements. Below, we present a staged framework for implementing effective GMP measures tailored to major dosage form categories.

Step 1: Identifying and Characterizing Packaging Materials Relative to Dosage Forms

The initial step in managing E&L risks is a systematic identification and characterization of the packaging materials used for each dosage form. Packaging components may include blister packs, bottles, vials, pumps, inhaler assemblies, and secondary packaging. Each material type – such as polymers, glass, rubber, and adhesives – possesses distinct chemical profiles that may contribute extractable substances.

• Solid oral dosage forms: Packaging often involves blister packs composed of PVC, PVDC, or aluminum foil and plastic bottles with child-resistant closures. Understanding polymer composition and potential additives from tablet manufacturing and capsule GMP operations is essential.
• Parenteral products: Vials and prefilled syringes made of glass or cyclic olefin polymers are typical. Rubber stoppers and lubricants present leachable risk factors that require profiling aligned with sterile injectables protocols.
• Topical formulations: Tubes, jars, and pumps made from various plastics can interact with ointments or creams, potentially releasing plasticizers or stabilizers into the product.
• Combination products, such as inhalers or drug-device assemblies, bring complexity due to multiple materials interfacing with active ingredients in a form sensitive to inhalation product regulatory requirements.

Analytical techniques such as Fourier-transform infrared spectroscopy (FTIR), gas chromatography-mass spectrometry (GC-MS), and high-performance liquid chromatography (HPLC) should be applied for material characterization under GMP-controlled laboratory conditions. Documenting the nature and concentration of potential extractables forms the basis for risk assessment and downstream control.

Key Regulatory Considerations

Per FDA’s guidance on container closure systems, comprehensive assessment of materials in direct contact with pharmaceuticals is mandatory. The EMA and MHRA also require a risk-based approach to material qualification, confirming compliance with defined specifications throughout manufacturing and supply chain operations.

Step 2: Conducting Risk Assessment Based on Dosage Form and Packaging Interaction

With material data in hand, the next central step is a risk assessment structured to evaluate the likelihood and impact of extractables and leachables from the packaging system into the drug product. This assessment must be dosage form-specific because interaction dynamics vary significantly.

• Solid oral forms (tablets and capsules): Risk is typically lower compared to parenterals; however, the potential for plasticizer migration or interaction from blister foil adhesives exists. Tablet manufacturing processes also necessitate ensuring no contamination from packaging-related sources during handling and storage.
• Parenteral preparations: Highest risk level due to direct systemic administration. Rubber closures may leach N-nitrosamines or vulcanizing agents. Sterile injectable GMP frameworks demand strict environmental control, validated cleaning, and packaging with minimal extractables.
• Topical dosage forms: Risk assessment includes evaluating the compatibility of excipients with packaging polymers. Ointment components such as ointment bases or emulsifiers can enhance migration of extractables into the formulation.
• Combination and inhalation products: Complex assessments must consider device mechanics and user interaction. Materials in contact with the drug during aerosolization or actuation require qualification per inhalation product GMP standards.

The risk matrix should factor in toxicological thresholds, estimated patient exposure, and duration of contact. Identification of high-risk materials triggers enhanced control strategies, including tighter material specifications and end-product testing.

Documentation and Integration

A comprehensive risk assessment report should be maintained and updated per changes in packaging materials, formulation, or regulatory updates. This report forms an integral part of the Quality Management System (QMS) and supports regulatory submissions and audits.

Step 3: Analytical Method Development and Validation for E&L Testing

Following risk assessment, the design, development, and validation of analytical methods capable of detecting and quantifying extractables and leachables are mandatory GMP requirements. These methods must be suitably sensitive and specific, tailored to the dosage form matrix and anticipated contaminants.

• Method selection: Typically involves chromatographic techniques (GC-MS, LC-MS/MS), spectroscopy, and other hyphenated methods ensuring comprehensive chemical profiling.
• Matrix considerations: Different dosage forms require distinct sample preparation techniques to avoid interference. For example, solid oral forms may need dissolution steps before analysis, whereas parenteral samples require aseptic handling and minimal extraction steps to simulate real-use conditions.
• Validation parameters: Include accuracy, precision, linearity, limit of detection (LOD), limit of quantitation (LOQ), specificity, and robustness in compliance with ICH Q2(R1) guidelines.
• Reference standards and controls: Pure compounds of expected extractables should be used to confirm identity and quantitation. Procedural blanks and spiked controls ensure analytical reliability within GMP environments.

For sterile injectables and inhalation products, validated cleanroom sampling and testing procedures aligned with PIC/S PE 009 Good Practices for Sampling are essential, ensuring sample integrity and compliance with inspection expectations.

Step 4: Defining and Implementing GMP Controls in Manufacturing and Packaging Processes

Once E&L risks are quantified and analytical capabilities established, robust GMP controls must be systematically integrated into manufacturing and packaging workflows. These controls ensure consistent compliance and patient protection across dosage forms:

• Material specifications and supplier qualification: Extended specifications for packaging and closure materials should be established with detailed limits for potential extractables. Supplier audits and qualification must confirm compliance with GMP and regulatory standards.
• Qualification of container closure systems: Validation studies verifying closure integrity and leachables profiles throughout product shelf-life are mandatory, especially for sterile injectables.
• In-process controls (IPC): Real-time monitoring of critical parameters in tablet manufacturing and capsule GMP processes help mitigate contamination risks. IPC for sterile injectables encompasses environmental monitoring and sterile filtration validation.
• Controlled storage and handling: Packaging components and finished products must be stored under conditions minimizing interactions, such as temperature and humidity controls, segregation, and inventory management compliant with EU GMP Volume 4 Annex 15.
• Change control and continuous monitoring: Any change in packaging materials, suppliers, or formulation triggers re-evaluation of E&L risk assessments and testing to maintain GMP compliance.

Documented standard operating procedures (SOPs) covering these controls and employee training ensure consistent implementation and inspection readiness.

Step 5: Stability Studies and Ongoing Monitoring of Extractables and Leachables

An essential phase in the GMP lifecycle is the execution of stability studies tailored to both product and packaging combination. Evaluating leachables as part of real-time and accelerated stability studies confirms that packaging-drug interactions remain within safety limits throughout shelf life.

Pharmaceutical manufacturers should:

• Include extractables and leachables assessment as predetermined stability-indicating attributes.
• Document all deviations, trends, or emergent impurities related to packaging materials.
• Perform periodic review and trending of E&L data, ensuring trending analyses detect any increase beyond established action limits.
• Assess patient safety implications when unexpected leachables arise, applying toxicological risk assessments per ICH Q3C residual solvents and Q9 quality risk management principles.

These continuous monitoring activities support post-approval change management and assure regulatory inspectors that GMP and pharmacovigilance standards are met.

Conclusion: Integrating Dosage Form-Specific GMP for E&L Compliance

Effective control of extractables and leachables at the interface of dosage form and packaging is a multidisciplinary GMP endeavor requiring expertise across formulation, quality control, manufacturing, and regulatory affairs. Through a structured approach—characterizing packaging materials, conducting dosage-form specific risk assessments, developing validated analytical methods, instituting GMP controls in manufacturing, and maintaining ongoing monitoring—pharmaceutical companies ensure that products meet rigorous safety and compliance standards demanded by FDA, EMA, MHRA, PIC/S, and WHO regulators.

Following this step-by-step tutorial enables pharma professionals to proactively address E&L challenges affecting solid oral, parenteral, topical, inhalation, and combination products. This strategic approach mitigates risks, supports regulatory inspections, and ultimately upholds patient safety and product efficacy in global pharmaceutical markets.